✦ LIBER ✦

P.1.183 Mirtazapine vs amitriptyline and placebo in the treatment of severely depressed patients

✍ Scribed by S. Kasper

Book ID: 118599919
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 134 KB
Volume: 7
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(97)88631-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mirtazapine vs amitriptyline and placebo

Mirtazapine vs amitriptyline and placebo in the treatment of severely depressed patients

✍ Wingard, P.; Panagides, J. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 232 KB

P-4-2 - Mirtazapine vs tricyclic antidep

P-4-2 - Mirtazapine vs tricyclic antidepressants in the treatment of severely depressed patients

✍ M. Zivkov; A. Mühring 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 152 KB

P.1.003 - Efficacy of mirtazapine vs clo

P.1.003 - Efficacy of mirtazapine vs clomipramine in severely depressed, hospitalized patients

✍ E. Peyron 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 140 KB

P.1.008 - Mirtazapine versus tricyclic a

P.1.008 - Mirtazapine versus tricyclic antidepressants in the treatment of severely depressed patients

✍ M. Zivkov; A. Mühring; C.M.E. Kremer 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 307 KB

Pharmacological treatment of severely de

Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline

✍ S Kasper; M Zivkov; K.C.B Roes; A.G Pols 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Cianopramine and amitriptyline in the tr

Cianopramine and amitriptyline in the treatment of depressed patients — a placebo-controlled study

✍ L. Hormazabal; L. M. O. Omer; S. Ismail 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 330 KB

3-Cyano-imipramine (cianopramine) is a potent and selective inhibitor of serotonin uptake into synaptosomes. In a double-blind trial, 60 patients with various types of depression fulfilling the DSM-III criteria of depressive episodes were treated with either cianopramine (n=20, mean daily dose 3.3\_